These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 6742767)

  • 21. Prognostic value of raised prostatic acid phosphatase and negative skeletal scintigraphy in prostatic cancer.
    Goodman CM; Cumming JA; Ritchie AW; Chisholm GD
    Br J Urol; 1991 Jun; 67(6):622-5. PubMed ID: 2070208
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The flare phenomenon on radionuclide bone scan in metastatic prostate cancer.
    Pollen JJ; Witztum KF; Ashburn WL
    AJR Am J Roentgenol; 1984 Apr; 142(4):773-6. PubMed ID: 6230903
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunoscintigraphy With 99mTc-Nimotuzumab for Planning Immunotherapy in Patients With Bone Metastases Due to Prostate Cancer.
    Quián YP; Crombet T; Batista JF; Prats A; Perera A
    Clin Nucl Med; 2016 Mar; 41(3):244-6. PubMed ID: 26447381
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Radiologic diagnosis of bone metastases recurrence in patients with prostate cancer treated strontium-89].
    Barysheva EV; Selivanov SP; Riannel' IuE; Velichko SA; Usynin EA; Usov VIu
    Vestn Rentgenol Radiol; 1999; (5):32-6. PubMed ID: 12717923
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of unlabelled monoclonal antibodies on the biodistribution of 111In-labelled anti-prostate-specific acid phosphatase monoclonal antibodies in the mouse model.
    Peräalä-Heape M; Vihko P; Vihko R
    Anticancer Res; 1991; 11(3):1327-31. PubMed ID: 1888168
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Correlation between extent of metastatic lesions in whole body bone scintigraphy of patients with prostatic cancer and prostatic acid phosphatase in serum with Eiken PAP RIA kit.
    Kida T; Higuchi Y
    Oncology; 1983; 40(5):346-50. PubMed ID: 6621997
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Positron emission tomography and molecular imaging of the prostate: an update.
    Lawrentschuk N; Davis ID; Bolton DM; Scott AM
    BJU Int; 2006 May; 97(5):923-31. PubMed ID: 16643472
    [No Abstract]   [Full Text] [Related]  

  • 28. [Osseous scintigraphy in prostatic cancer. Diagnostic and developmental significance].
    Oliveux A; Grob JC; Methlin G; Cinqualbre J; Pellerin JP; Bollack C
    Rev Med Suisse Romande; 1980 Nov; 100(11):905-8. PubMed ID: 7466062
    [No Abstract]   [Full Text] [Related]  

  • 29. Prostate cancer. Nuclear medicine.
    Merrick MV; Stone AR; Chisholm GD
    Recent Results Cancer Res; 1981; 78():108-18. PubMed ID: 7022591
    [No Abstract]   [Full Text] [Related]  

  • 30. [Radionuclide diagnosis and therapy of skeletal metastases of prostatic cancer].
    Schümichen C
    Radiologe; 1984 Jan; 24(1):13-8. PubMed ID: 6200897
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Atypical bone metastases in prostate cancer].
    Sciuk J; Kirchner B
    Aktuelle Radiol; 1991 May; 1(3):134-7. PubMed ID: 1878383
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bone scanning and plasma phosphatases in carcinoma of the prostate.
    O'Donoghue EP; Constable AR; Sherwood T; Stevenson JJ; Chisholm GD
    Br J Urol; 1978 May; 50(3):172-7. PubMed ID: 753455
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Early detection of bone metastases in carcinoma of the prostate using the gamma camera].
    Flores Corral N; Unda M; Jorge A; Arregui R; Prieto N
    Arch Esp Urol; 1985; 38(2):131-6. PubMed ID: 4026394
    [No Abstract]   [Full Text] [Related]  

  • 34. [Value of prostatic acid phosphatase and its relation to bone gammagraphy in the diagnosis of cancer of the prostate].
    González Alenda FJ; Castro Beiras JM; Martín Curto LM; Avila Blanco C; Crespo Díez A
    Rev Clin Esp; 1983 Oct; 171(1):47-50. PubMed ID: 6658082
    [No Abstract]   [Full Text] [Related]  

  • 35. Radioimmunodetection of prostate cancer by 111In-labeled monoclonal antibody against prostatic acid phosphatase.
    Ahonen A; Kairemo K; Karnani P; Heikkilä J; Nurmi M; Teräs M; Lukkarinen O
    Acta Oncol; 1993; 32(7-8):723-7. PubMed ID: 8305218
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prostate cancer imaging with a new monoclonal antibody: a preliminary report.
    Sanford E; Grzonka R; Heal A; Helal M; Persky L; Tyson I
    Ann Surg Oncol; 1994 Sep; 1(5):400-4. PubMed ID: 7850541
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Purification of monoclonal antibodies raised against prostate-specific acid phosphatase for use in vivo in radioimaging of prostatic cancer.
    Hakalahti L; Vihko P
    J Immunol Methods; 1989 Feb; 117(1):131-6. PubMed ID: 2913158
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Significance of skeletal scintigraphy for oncological practice].
    Kampmann H; Buchelt L
    Rontgenblatter; 1983 Oct; 36(10):342-51. PubMed ID: 6227979
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Metastatic prostatic pulmonary nodules with normal bone image.
    Petras AF; Wollett FC
    J Nucl Med; 1983 Nov; 24(11):1026-7. PubMed ID: 6226768
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Comparative evaluation of serum acid phosphatases, conventional x-ray diagnosis, bone biopsy and Sr 85-bone scanning in the diagnosis of osseous metastases in cancer of the prostate].
    Graber P; Rutishauser G; Baumann JM
    Urologe; 1971 Mar; 10(2):60-2. PubMed ID: 5577980
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.